On 22 December 2025, B&K Corporation Limited (B&K Corp, 2396.HK) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), raising a total of approximately HKD 674 million. CBI is honored to participate in the due diligence work for this IPO Project.

B&K Corp is a China-based company principally engaged in the research and development of biopharmaceutical products. The Company committed to developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities. The Company primarily focus on the discovery, development and commercialization of therapies for wound healing, currently PDGF drugs. 

In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the company group, its directors, senior management, shareholders, customers and suppliers, etc. In addition to the basic information such as litigation, bankruptcy, winding-up and media records, CBI also assisted the sponsor team in conducting reputation intelligence and related company search. The due diligence project mainly covered China and Hong Kong.